Outcome of Transplantation for Myelofibrosis

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 3, 2010, Pages 358-367

  Ballen, Karen K ^a   Shrestha, Smriti ^b   Sobocinski, Kathleen A ^b   Zhang, Mei Jie ^b   Bashey, Asad ^c   Bolwell, Brian J ^d   Cervantes, Francisco ^e   Devine, Steven M ^f   Gale, Robert Peter ^g   Gupta, Vikas ^h   Hahn, Theresa E ⁱ   Hogan, William J ^j   Kröger, Nicolaus ^k   Litzow, Mark R ^j   Marks, David I ^l   Maziarz, Richard T ^m   McCarthy, Philip L ⁱ   Schiller, Gary ⁿ   Schouten, Harry C ^o   Roy, Vivek ^p   Wiernik, Peter H ^q   Horowitz, Mary M ^b   Giralt, Sergio A ^r   Arora, Mukta ^s   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c Blood and Marrow Transplant Group of Georgia   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^f THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^g CELGENE CORPORATION   (United States)

^h PRINCESS MARGARET HOSPITAL   (Canada)

ⁱ ROSWELL PARK CANCER INSTITUTE   (United States)

^j MAYO CLINIC ROCHESTER   (United States)

^k UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^l United Bristol Healthcare   (United Kingdom)

^m OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^p MAYO CLINIC   (United States)

^q NEW YORK MEDICAL COLLEGE   (United States)

^r UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^s UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

more..

Author keywords

Allogeneic transplantation; Myelofibrosis

Indexed keywords

CYCLOSPORIN; METHOTREXATE; TACROLIMUS;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENGRAFTMENT; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; MYELOFIBROSIS; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; RECURRENCE RISK; SIBLING; SPLENECTOMY; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; KAPLAN-MEIERS ESTIMATE; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PRIMARY MYELOFIBROSIS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SIBLINGS; SPLENOMEGALY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 75749125700     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.10.025     Document Type: Article

References (42)

1. Silverstein M.N. Myeloproliferative disease. Curr Hematol Oncol 6 (1988) 163-184
2. Tefferi A. The forgotten myeloproliferative disorder: myeloid metaplasia. Oncologist 8 (2003) 225-231
3. Dupriez B., Morel P., Demory J.L., et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 88 (1996) 1013-1018
4. Cervantes F., Pereira A., Esteve J., et al. Identification of "short-lived" and "long-lived" patients at presentation of idiopathic myelofibrosis. Br J Haematol 97 (1997) 635-640
5. Cervantes F., Barosi G., Demory J.L., et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 102 (1998) 684-690
6. Cervantes F., Dupriez B., Pereira A., et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113 (2009) 2895-2901
7. Vannucchi A.M., Bianchi L., Cellai C., et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). Blood 100 (2002) 1123-1132
8. Vannucchi A.M., Bianchi L., Paoletti F., et al. A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis. Blood 105 (2005) 3493-3501
9. Barosi G., Bergamaschi G., Marchetti M., et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 110 (2007) 4030-4036
10. Hennessy B.T., Thomas D.A., Giles F.J., Kantarjian H., and Verstovsek S. New approaches in the treatment of myelofibrosis. Cancer 103 (2005) 32-43
11. Mesa R.A., Steensma D.P., Pardanani A., et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 101 (2003) 2534-2541
12. Bachleitner-Hofmann T., and Gisslinger H. The role of interferon-alpha in the treatment of idiopathic myelofibrosis. Ann Hematol 78 (1999) 533-538
13. Cervantes F. Modern management of myelofibrosis. Br J Haematol 128 (2005) 583-592
14. Verstovsek S.P.A., Shah N.P., et al. A Phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 110 (2007) 553a abstract
15. Guardiola P., Anderson J.E., Bandini G., et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 93 (1999) 2831-2838
16. Daly A., Song K., Nevill T., et al. Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplant 32 (2003) 35-40
17. Deeg H.J., Gooley T.A., Flowers M.E., et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 102 (2003) 3912-3918
18. Kerbauy D.M., Gooley T.A., Sale G.E., et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant 13 (2007) 355-365
19. Rondelli D., Barosi G., Bacigalupo A., et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 105 (2005) 4115-4119
20. Kroger N., Zabelina T., Schieder H., et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 128 (2005) 690-697
21. Farag S.S., Bacigalupo A., Eapen M., et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant 12 (2006) 876-884
22. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18 (1974) 295-304
23. Cox D.R. Regression models and life tables. J R Stat Soc 34 (1972) 187-202
24. Weisdorf D., Spellman S., Haagenson M., et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 14 (2008) 748-758
25. Giralt S., Ballen K., Rizzo D., et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 15 (2009) 367-369
26. Anderson J.E., Tefferi A., Craig F., et al. Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. Blood 98 (2001) 586-593
27. Mittal P., Saliba R.M., Giralt S.A., et al. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Bone Marrow Transplant 33 (2004) 1005-1009
28. Ditschkowski M., Beelen D.W., Trenschel R., Koldehoff M., and Elmaagacli A.H. Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplant 34 (2004) 807-813
29. Barosi G., and Bacigalupo A. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Curr Opin Hematol 13 (2006) 74-78
30. Patriarca F., Bacigalupo A., Sperotto A., et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica 93 (2008) 1514-1522
31. Tefferi A., Barosi G., Mesa R.A., et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 108 (2006) 1497-1503
32. Li Z., Gooley T., Applebaum F.R., and Deeg H.J. Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. Blood 97 (2001) 2180-2181
33. Barosi G., Ambrosetti A., Buratti A., et al. Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. Leukemia 7 (1993) 200-206
34. Tefferi A., Mesa R.A., Nagorney D.M., Schroeder G., and Silverstein M.N. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 95 (2000) 2226-2233
35. Kroger N., Badbaran A., Holler E., et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 109 (2007) 1316-1321
36. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 (1998) 756-763
37. Dey B.R., McAfee S., Sackstein R., et al. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation. Biol Blood Marrow Transplant 7 (2001) 604-612
38. Devine S.M., Hoffman R., Verma A., et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 99 (2002) 2255-2258
39. Giralt S., Thall P.F., Khouri I., et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97 (2001) 631-637
40. Merup M., Lazarevic V., Nahi H., et al. Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br J Haematol 135 (2006) 367-373
41. Kroger N., and Mesa R.A. Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia 22 (2008) 474-486
42. Maziarz R.T., Mesa R.A., and Tefferi A. Allogeneic stem cell transplantation for chronic myeloproliferative disorders and myelodysplastic syndromes: the question is "when?". Mayo Clin Proc 78 (2003) 941-943